Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
Qualifying a biological starting material supplier for an IND is not a vendor evaluation — it is a regulatory exercise that needs to produce documentation FDA can audit. The agency does not require you to use any particular supplier, but it does require that you demonstrate your chosen supplier meets applicable manufacturing standards, that you understand their process controls, and that your lot release criteria reflect meaningful quality oversight of incoming material.
Most sponsor teams underestimate how much supplier qualification documentation actually needs to be in the IND package and in the Quality Agreement before the first clinical lot ships. This guide covers the regulatory framework, the documentation you need to collect, the questions your audit needs to answer, and a checklist you can use as a starting point when qualifying an HCT/P or biological starting material supplier.
The Regulatory Framework
Starting materials for cell therapy INDs fall under two primary regulatory frameworks depending on how they are classified and used:
21 CFR Part 1271 (HCT/Ps): Human Cells, Tissues, and Cellular and Tissue-Based Products. Applies to human-derived starting materials — leukopaks, PBMCs, cord blood, bone marrow, and similar biologics. Suppliers must be registered with FDA and comply with Part 1271 donor eligibility, donor screening, and testing requirements. For materials used in clinical manufacturing, the supplier must also comply with Part 1271 Subpart C (processing and distribution) and maintain a registered establishment.
21 CFR Parts 210 and 211 (cGMP for drugs): Apply to the manufacturing process for the investigational drug product — the cellular therapy itself. The starting material supplier’s operations may not be subject to 210/211 directly, but your manufacturing process, which uses the starting material as an input, is. This means your incoming material specifications and lot release criteria must be defined tightly enough to demonstrate your drug substance manufacturing process is controlled.
21 CFR Part 312 (IND regulations): Your IND must describe the manufacturing and testing of the investigational drug product, including the source and characterization of starting materials (21 CFR 312.23(a)(7)). FDA’s chemistry, manufacturing, and controls (CMC) section reviewers will look at your starting material sourcing as part of their review of whether the product can be manufactured consistently and safely for clinical use.
FDA Guidance on CGMP for Phase 1 Investigational Drugs (2008, updated) and FDA Guidance on Potency Testing for Cellular and Gene Therapy Products (2011) are the primary FDA guidance documents for Phase 1 cell therapy CMC. They explicitly address the need to characterize starting material identity, purity, and potency-related attributes.
What Supplier Qualification Documentation You Need
FDA expects that you have evaluated your starting material supplier and can demonstrate that evaluation in your IND file and in your Quality Agreement. The minimum documentation package includes:
1. Supplier qualification questionnaire and audit record
A completed questionnaire covering the supplier’s regulatory registrations, quality management system, SOPs for collection and processing, change notification procedures, and deviation/CAPA practices. Either an on-site audit report or a remote audit record signed by a qualified person. Many Phase 1 programs conduct remote audits, which FDA generally accepts for early-phase INDs, though on-site audits for Phase 2 and Phase 3 programs are more common expectations.
2. Certificate of Analysis (CoA) template and review
A copy of the supplier’s standard CoA for the material you will receive. You should review this document and define your acceptance criteria for each CoA parameter before the first lot is received. FDA will expect to see that your CoA review process is documented in a SOP and that you have defined what constitutes a passing lot and a failing lot.
3. Donor eligibility determination records
For HCT/P starting materials under Part 1271, the supplier must perform donor screening and testing and issue a donor eligibility determination (DED). You must receive the DED or an abbreviated summary that confirms the donor was determined eligible before the material was released. Retain these records. FDA may inspect them.
4. Quality Agreement
A signed Quality Agreement (QA) between your organization and the supplier that defines responsibilities for: donor eligibility and testing, material testing and release, deviation notification and CAPA, change notification (process changes, facility changes, regulatory changes that affect the material), and retention of records supporting IND filing. Quality Agreements are not required by regulation to be in a specific form, but FDA has stated in guidance that they are a cGMP expectation for Phase 2 and beyond, and many Phase 1 reviewers look for them as evidence of quality oversight.
5. Material specification
Your written specification for the incoming starting material: identity tests (cell type confirmation, viability), purity (subset frequencies, red cell contamination), safety (sterility or bioburden, endotoxin if applicable, infectious disease panel results from supplier), and potency-related attributes (for NK programs: cytotoxicity; for T cell programs: activation response). These are your incoming quality release criteria — the test results you require before releasing the lot for manufacturing use.
6. Testing records and incoming material release logs
Records showing that each received lot was tested against your specification, reviewed, and released (or rejected) by a designated qualified person. Phase 1 programs can maintain these in electronic or paper format, but they must be retrievable for inspection.
The Audit: What Questions Need Answers
Whether remote or on-site, your supplier audit needs to verify specific capabilities and practices. The questions below are organized by the regulatory areas FDA cares about most:
FDA Registration and Regulatory Status
- Is the supplier registered with FDA as an HCT/P establishment under 21 CFR 1271.10?
- Is the registration current (annual renewal or as required)?
- Has the supplier received any 483 observations or warning letters in the past three years? What was the nature, and what CAPA was implemented?
- Does the supplier operate under any consent decree or voluntary action indicated (VAI) status?
Donor Eligibility and Screening
- What is the donor screening procedure (questionnaire, physical examination, medical history review)?
- What infectious disease testing panel is performed on each donor? (Required: anti-HIV-1/2, HBsAg, anti-HBc, anti-HCV, anti-HTLV-I/II, Treponema pallidum — see 21 CFR 1271.85)
- Who performs the donor eligibility determination, and are they a licensed physician?
- How are ineligible donors handled, and how are records of ineligible determinations retained?
- What is the procedure for deferred or repeat donors?
Collection and Processing
- What apheresis instruments are used? Are they validated and calibrated?
- What SOPs govern the collection procedure?
- Where does processing occur (same facility as collection, or shipped to a secondary processing site)?
- What are the environmental controls for processing (cleanroom grade, air classification)?
- What is the maximum allowable time from collection to processing, and how is this monitored?
- For cryopreserved products: what cryoprotectant is used, what is the controlled-rate freezing protocol, and how is liquid nitrogen storage managed?
Quality Management System
- Does the supplier have a documented QMS? Can they provide the QMS overview?
- How are deviations from SOPs documented and escalated?
- What is the CAPA procedure for material quality failures?
- How does the supplier notify customers of deviations that may affect released material?
- What is the process change notification procedure, and what triggers a mandatory customer notification?
- Are internal audits conducted? When was the last internal audit, and what were the findings?
Testing and Release
- What tests does the supplier perform on each lot before release?
- Who reviews and releases the material (qualified QA person or designee)?
- What is retained on the lot and for how long?
- Can the supplier perform additional characterization tests on request (HLA typing, KIR genotyping, cell subset frequencies, NK cytotoxicity)?
Traceability
- Can the supplier trace each received lot back to a specific donor and a specific collection event?
- Is there a unique lot number system for material traceability?
- How long are traceability records retained?
Lot Release Criteria: What to Specify
Your incoming specification should define acceptance criteria for each test that you perform or rely on the supplier to perform. A minimal specification for leukopak or PBMC starting material in a clinical manufacturing program typically covers:
- Viability: ≥ 70% viable cells by trypan blue or equivalent (many programs specify ≥ 80–90% for fresh product)
- Total nucleated cell count: within the range specified in the purchase order or Quality Agreement
- Donor eligibility status: confirmed eligible per 21 CFR 1271 donor eligibility determination
- Infectious disease panel: negative for HIV-1/2, HBsAg, anti-HBc, anti-HCV, anti-HTLV-I/II, RPR/syphilis
- Sterility or bioburden: negative (14-day aerobic/anaerobic sterility or 7-day bioburden per USP <71>, or supplier equivalent)
- Cell identity: confirmation of CD45+ leukocyte majority by flow or supplier documentation
- Optional: subset phenotyping (CD3+CD4+, CD3+CD8+, CD56+CD3−, CD19+) if donor-to-donor consistency is required for process inputs
For programs requiring donor characterization data (HLA type, KIR genotype, CMV serostatus), these should also be specified in your incoming specification and documented in the CoA for each lot used in manufacturing.
IND Filing: What FDA Reviewers Look For
FDA’s CMC reviewers for cell therapy INDs typically check the following in your starting material section (Section 3.2.S.2 of the eCTD module or the equivalent CMC section in your IND):
- Identification of the starting material source (supplier name, location, registration number)
- Description of the collection procedure and processing steps
- Donor eligibility and testing procedures (or reference to supplier’s Part 1271 registration and compliance)
- Specification for the starting material with acceptance criteria
- Testing performed on each lot before use in manufacturing
- Characterization data from development lots showing the starting material is consistent with your process inputs
Phase 1 reviewers generally apply a risk-based standard — they expect more rigor on starting material characterization for allogeneic programs (where donor-to-donor variability directly affects safety and efficacy) than for autologous programs. But autologous programs still need documented lot release and donor eligibility records.
Qualification Checklist
Use this as a starting template. Adapt to your program’s specific starting material and regulatory status:
Documentation to collect before first lot receipt:
- ☐ FDA establishment registration number (confirm current status on FDA website)
- ☐ Recent 483 or warning letter history (ask directly; check FDA enforcement database)
- ☐ QMS overview or quality manual (scope, organizational structure, key SOPs list)
- ☐ Completed supplier qualification questionnaire (your template)
- ☐ Sample CoA for the material type you will receive
- ☐ Sample donor eligibility determination or abbreviated DED summary
- ☐ Signed Quality Agreement covering notification, CAPA, change control, record retention
- ☐ Apheresis/processing facility description (square footage, ISO classification if applicable)
- ☐ Internal audit results (last 12 months)
- ☐ List of SOPs governing donor screening, collection, processing, testing, and release
Material specification to finalize before first manufacturing lot:
- ☐ Viability acceptance criterion
- ☐ Total cell count specification
- ☐ Donor eligibility status requirement
- ☐ Infectious disease panel requirement (tests and results)
- ☐ Sterility/bioburden requirement
- ☐ Cell identity test
- ☐ Subset phenotype requirements (if applicable)
- ☐ HLA, KIR, CMV requirements (if applicable)
Ongoing lot release procedure:
- ☐ Incoming material receipt and logging SOP
- ☐ CoA review by designated QA or qualified person
- ☐ Incoming lot testing (if you perform additional testing beyond supplier CoA)
- ☐ Lot release/rejection decision record
- ☐ Quarantine procedure for lots pending release
- ☐ Handling procedure for rejected lots (destruction, return, segregation)
Working with OrganaBio as an IND Starting Material Supplier
OrganaBio is an FDA-registered HCT/P establishment under 21 CFR Part 1271. HemaCenter, OrganaBio’s apheresis collection subsidiary, performs donor screening, eligibility determination, and collection under Part 1271-compliant SOPs. OrganaBio can provide:
- Current FDA establishment registration documentation
- Standard CoA covering viability, cell count, infectious disease testing, and donor eligibility status
- Donor eligibility determination summaries for each lot
- Qualified personnel for remote audit participation
- Quality Agreement execution with defined notification and CAPA provisions
- Extended characterization CoA options: HLA class I/II, KIR genotyping, CMV serostatus, cell subset phenotyping
- IND support documentation on request
Contact OrganaBio’s team to discuss supplier qualification support for your IND program through the contact page or to request our standard supplier qualification package.
